DreamCIS Inc Cash Flow Conversion Efficiency
DreamCIS Inc cash flow conversion efficiency. Based on the latest financial reports, DreamCIS Inc (223250) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.17 Billion ≈ $1.47 Million USD) by net assets (₩92.81 Billion ≈ $62.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of DreamCIS Inc (2017–2024)
Cash flow conversion efficiency of DreamCIS Inc from 2017 to 2024. This chart illustrates how DreamCIS Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of DreamCIS Inc for real-time trading data and today's change.
DreamCIS Inc Cash Flow Conversion Ratio Explained
DreamCIS Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
DreamCIS Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DreamCIS Inc ranked by their cash flow conversion efficiency. Also see DreamCIS Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Energy Transition Minerals Ltd
AU:ETM
|
-0.101x |
|
MedFirst Healthcare Services lnc
TWO:4175
|
0.076x |
|
Electrocore LLC
NASDAQ:ECOR
|
2.339x |
|
Powertech Industrial Co Ltd
TW:3296
|
-0.016x |
|
TV Today Network Limited
NSE:TVTODAY
|
-0.051x |
|
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
|
0.156x |
|
Pinar Sut Mamulleri Sanayi AS
IS:PNSUT
|
0.025x |
|
Alterity Therapeutics Limited
F:PBN
|
-0.093x |
Annual Cash Flow Conversion Efficiency for DreamCIS Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of DreamCIS Inc from 2017 to 2024. Review free cash flow generation of DreamCIS Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩67.96 Billion ≈ $46.06 Million |
₩-85.19 Million ≈ $-57.73K |
-0.001x | -100.97% |
| 2023-12-31 | ₩56.93 Billion ≈ $38.58 Million |
₩7.33 Billion ≈ $4.97 Million |
0.129x | -30.57% |
| 2022-12-31 | ₩48.96 Billion ≈ $33.18 Million |
₩9.08 Billion ≈ $6.16 Million |
0.186x | +19.79% |
| 2021-12-31 | ₩37.98 Billion ≈ $25.74 Million |
₩5.88 Billion ≈ $3.99 Million |
0.155x | +65.10% |
| 2020-12-31 | ₩36.46 Billion ≈ $24.71 Million |
₩3.42 Billion ≈ $2.32 Million |
0.094x | -76.46% |
| 2019-12-31 | ₩10.75 Billion ≈ $7.28 Million |
₩4.28 Billion ≈ $2.90 Million |
0.398x | -46.58% |
| 2018-12-31 | ₩6.51 Billion ≈ $4.41 Million |
₩4.85 Billion ≈ $3.29 Million |
0.746x | +27.42% |
| 2017-12-31 | ₩2.82 Billion ≈ $1.91 Million |
₩1.65 Billion ≈ $1.12 Million |
0.585x | -- |
About DreamCIS Inc
DreamCIS, Inc. operates as a clinical research organization in South Korea. It offers clinical development services; biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headqua… Read more